Clinical trials
Observational Fabry Disease trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Yonsei University | 4 |
| Chang Gung Memorial Hospital | 2 |
| Lysosomal and Rare Disorders Research and Treatment Center, Inc. | 2 |
| O & O Alpan LLC | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Caroline Michaela Kistorp | 1 |
| Cedars-Sinai Medical Center | 1 |
| Chiayi Christian Hospital | 1 |
| First Hospital of China Medical University | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fabry Disease | 30 |
| Lysosomal Storage Diseases | 4 |
| Gaucher Disease | 3 |
| Glycogen Storage Disease Type II | 3 |
| Hypertrophy, Left Ventricular | 3 |
| Cardiomyopathy, Hypertrophic | 2 |
| Kidney Failure, Chronic | 2 |
| Niemann-Pick Diseases | 2 |
| Alzheimer Disease | 1 |
| Amyloid Neuropathies, Familial | 1 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.